Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,717 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Fukuokaya W, Yanagisawa T, Hashimoto M, Yamamoto S, Koike Y, Imai Y, Iwatani K, Onuma H, Ito K, Urabe F, Tsuzuki S, Kimura S, Miki J, Oyama Y, Abe H, Kimura T. Fukuokaya W, et al. Among authors: hashimoto m. Cancer Immunol Immunother. 2023 Apr;72(4):841-849. doi: 10.1007/s00262-022-03291-5. Epub 2022 Sep 14. Cancer Immunol Immunother. 2023. PMID: 36102985 Free PMC article.
Presurgical immune-oncology/tyrosine kinase inhibitor combination therapy for renal cell carcinoma with a vena cava tumor thrombus: a single-institution case series.
Urabe F, Iwatani K, Hashimoto M, Suzuki H, Miyajima K, Murakami M, Tashiro K, Tsuzuki S, Furuta A, Sato S, Takahashi H, Kimura T. Urabe F, et al. Among authors: hashimoto m. Transl Androl Urol. 2023 Aug 31;12(8):1321-1325. doi: 10.21037/tau-23-203. Epub 2023 Aug 10. Transl Androl Urol. 2023. PMID: 37680224 Free PMC article.
Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.
Hara S, Mori K, Fukuokaya W, Tomomasa N, Oguchi T, Takahashi Y, Saito S, Katami J, Sano T, Kadena S, Hashimoto M, Yata Y, Nishi E, Suhara Y, Takamizawa S, Kurawaki S, Suzuki H, Miyajima K, Iwatani K, Urabe F, Ito K, Yanagisawa T, Tsuzuki S, Shimomura T, Kimura T. Hara S, et al. Among authors: hashimoto m. Int J Clin Oncol. 2024 Aug;29(8):1191-1197. doi: 10.1007/s10147-024-02548-6. Epub 2024 May 20. Int J Clin Oncol. 2024. PMID: 38769191
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study.
Urabe F, Imai Y, Goto Y, Tashiro K, Hashimoto M, Yoshihara K, Yamamoto S, Hara S, Miyajima K, Fukuokaya W, Enei Y, Iwatani K, Kayano S, Igarashi T, Aikawa K, Yanagisawa T, Kimura S, Tsuzuki S, Murakami M, Hata K, Shimomura T, Yamada H, Miki J, Kimura T. Urabe F, et al. Among authors: hashimoto m. Jpn J Clin Oncol. 2024 Nov 2;54(11):1208-1213. doi: 10.1093/jjco/hyae098. Jpn J Clin Oncol. 2024. PMID: 39037966
[UPFRONT DOCETAXEL WITH ANDROGEN DEPRIVATION THERAPY IN MALES WITH HIGH-VOLUME METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: RESULTS OF A SINGLE-INSTITUTION SERIES].
Hata K, Hashimoto M, Takahashi Y, Saito S, Kawaharada A, Enei Y, Tanaka M, Sakanaka K, Takahashi K, Hisakane A, Yanagisawa T, Tsuzuki S, Honda M, Furuta A, Miki K, Kimura T. Hata K, et al. Among authors: hashimoto m. Nihon Hinyokika Gakkai Zasshi. 2024;115(1):11-20. doi: 10.5980/jpnjurol.115.11. Nihon Hinyokika Gakkai Zasshi. 2024. PMID: 39828343 Free article. Japanese.
Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative study.
Taneda Y, Urabe F, Uchida N, Kadena S, Shibata K, Hashimoto M, Kawano S, Takiguchi Y, Ohtsuka T, Nakazono M, Imai Y, Iwatani K, Kayano S, Atsuta M, Tashiro K, Murakami M, Tsuzuki S, Yamamoto T, Yamada H, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Taneda Y, et al. Among authors: hashimoto m. Jpn J Clin Oncol. 2025 Jan 17:hyaf008. doi: 10.1093/jjco/hyaf008. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 39820356
4,717 results